298 related articles for article (PubMed ID: 33907490)
1. Clinical Utility of Pegaspargase in Children, Adolescents and Young Adult Patients with Acute Lymphoblastic Leukemia: A Review.
Bender C; Maese L; Carter-Febres M; Verma A
Blood Lymphat Cancer; 2021; 11():25-40. PubMed ID: 33907490
[TBL] [Abstract][Full Text] [Related]
2. Outcome of pediatric patients with acute lymphoblastic leukemia/lymphoblastic lymphoma with hypersensitivity to pegaspargase treated with PEGylated Erwinia asparaginase, pegcrisantaspase: A report from the Children's Oncology Group.
Rau RE; Dreyer Z; Choi MR; Liang W; Skowronski R; Allamneni KP; Devidas M; Raetz EA; Adamson PC; Blaney SM; Loh ML; Hunger SP
Pediatr Blood Cancer; 2018 Mar; 65(3):. PubMed ID: 29090524
[TBL] [Abstract][Full Text] [Related]
3. Acute lymphoblastic leukaemia: a guide to asparaginase and pegaspargase therapy.
Ettinger LJ; Ettinger AG; Avramis VI; Gaynon PS
BioDrugs; 1997 Jan; 7(1):30-9. PubMed ID: 18031078
[TBL] [Abstract][Full Text] [Related]
4. L-asparaginase in the treatment of patients with acute lymphoblastic leukemia.
Egler RA; Ahuja SP; Matloub Y
J Pharmacol Pharmacother; 2016; 7(2):62-71. PubMed ID: 27440950
[TBL] [Abstract][Full Text] [Related]
5. PEGylated
Verma A; Chen K; Bender C; Gorney N; Leonard W; Barnette P
Pediatr Hematol Oncol; 2019 Aug; 36(5):277-286. PubMed ID: 31296092
[TBL] [Abstract][Full Text] [Related]
6. FDA drug approval summary: pegaspargase (oncaspar) for the first-line treatment of children with acute lymphoblastic leukemia (ALL).
Dinndorf PA; Gootenberg J; Cohen MH; Keegan P; Pazdur R
Oncologist; 2007 Aug; 12(8):991-8. PubMed ID: 17766659
[TBL] [Abstract][Full Text] [Related]
7. The use of Erwinia asparaginase for adult patients with acute lymphoblastic leukemia after pegaspargase intolerance.
Horvat TZ; Pecoraro JJ; Daley RJ; Buie LW; King AC; Rampal RK; Tallman MS; Park JH; Douer D
Leuk Res; 2016 Nov; 50():17-20. PubMed ID: 27631159
[TBL] [Abstract][Full Text] [Related]
8. Pharmacokinetics-based integration of multiple doses of intravenous pegaspargase in a pediatric regimen for adults with newly diagnosed acute lymphoblastic leukemia.
Douer D; Aldoss I; Lunning MA; Burke PW; Ramezani L; Mark L; Vrona J; Park JH; Tallman MS; Avramis VI; Pullarkat V; Mohrbacher AM
J Clin Oncol; 2014 Mar; 32(9):905-11. PubMed ID: 24516026
[TBL] [Abstract][Full Text] [Related]
9. Safety, efficacy, and clinical utility of asparaginase in the treatment of adult patients with acute lymphoblastic leukemia.
Koprivnikar J; McCloskey J; Faderl S
Onco Targets Ther; 2017; 10():1413-1422. PubMed ID: 28331334
[TBL] [Abstract][Full Text] [Related]
10. Asparaginase in the Treatment of Acute Lymphoblastic Leukemia in Adults: Current Evidence and Place in Therapy.
Juluri KR; Siu C; Cassaday RD
Blood Lymphat Cancer; 2022; 12():55-79. PubMed ID: 35669980
[TBL] [Abstract][Full Text] [Related]
11. The cost-effectiveness of pegaspargase versus native asparaginase for first-line treatment of acute lymphoblastic leukaemia: a UK-based cost-utility analysis.
Hu X; Wildman KP; Basu S; Lin PL; Rowntree C; Saha V
Health Econ Rev; 2019 Dec; 9(1):40. PubMed ID: 31885053
[TBL] [Abstract][Full Text] [Related]
12. Desensitization using pegaspargase in the era of commercially available Erwinia: A single-institution report on efficacy, cost, and resource utilization.
Feldman K; Aaronson K; Gu T; Ige K; Southworth E; Sanchez L; Stieglitz E
Pediatr Blood Cancer; 2024 Apr; 71(4):e30891. PubMed ID: 38311802
[TBL] [Abstract][Full Text] [Related]
13. Pegaspargase: an alternative?
Holle LM
Ann Pharmacother; 1997 May; 31(5):616-24. PubMed ID: 9161659
[TBL] [Abstract][Full Text] [Related]
14. Activity and Toxicity of Intravenous Erwinia Asparaginase Following Allergy to E. coli-Derived Asparaginase in Children and Adolescents With Acute Lymphoblastic Leukemia.
Vrooman LM; Kirov II; Dreyer ZE; Kelly M; Hijiya N; Brown P; Drachtman RA; Messinger YH; Ritchey AK; Hale GA; Maloney K; Lu Y; Plourde PV; Silverman LB
Pediatr Blood Cancer; 2016 Feb; 63(2):228-33. PubMed ID: 26376459
[TBL] [Abstract][Full Text] [Related]
15. Pegaspargase-induced hypertriglyceridemia in a patient with acute lymphoblastic leukemia.
Lau KM; Saunders IM; Goodman A
J Oncol Pharm Pract; 2020 Jan; 26(1):193-199. PubMed ID: 30823860
[TBL] [Abstract][Full Text] [Related]
16. Asparaginase therapy in patients with acute lymphoblastic leukemia: expert opinion on use and toxicity management.
Sandley M; Angus J
Leuk Lymphoma; 2023 Apr; 64(4):776-787. PubMed ID: 36781296
[TBL] [Abstract][Full Text] [Related]
17. Pegaspargase in Practice: Minimizing Toxicity, Maximizing Benefit.
Riley DO; Schlefman JM; Vitzthum Von Eckstaedt V HC; Morris AL; Keng MK; El Chaer F
Curr Hematol Malig Rep; 2021 Jun; 16(3):314-324. PubMed ID: 33978914
[TBL] [Abstract][Full Text] [Related]
18. L-asparaginase treatment in acute lymphoblastic leukemia: a focus on Erwinia asparaginase.
Pieters R; Hunger SP; Boos J; Rizzari C; Silverman L; Baruchel A; Goekbuget N; Schrappe M; Pui CH
Cancer; 2011 Jan; 117(2):238-49. PubMed ID: 20824725
[TBL] [Abstract][Full Text] [Related]
19. Cost-Utility Analysis of Pegaspargase for the Treatment of Acute Lymphoblastic Leukemia in Greece.
Gourzoulidis G; Koulentaki M; Kattamis A; Bouzani M; Giatra C; Chotzagiannoglou V; Beletsi A; Kourlaba G
Clin Drug Investig; 2022 Nov; 42(11):999-1008. PubMed ID: 36227415
[TBL] [Abstract][Full Text] [Related]
20.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
[Next] [New Search]
